146 results
8-K
EX-99.1
RGEN
Repligen Corp.
12 Jun 08
Results of Operations and Financial Condition
12:00am
the assessment of pancreatic duct structures by magnetic resonance imaging (MRI). The Phase 3 study is a multi-center, baseline-controlled, single dose … . Detailed visual assessment of the pancreatic ducts is important in the assessment, diagnosis and treatment of diseases such as acute and chronic
8-K
EX-99.1
RGEN
Repligen Corp.
7 Jun 07
Results of Operations and Financial Condition
12:00am
, as an agent to improve the assessment of pancreatic duct structures by magnetic resonance imaging (MRI). The study showed an improvement … visual assessment of the pancreatic ducts and identification of structural abnormalities is important in the assessment, diagnosis and treatment
8-K
EX-99.1
RGEN
Repligen Corp.
8 Aug 07
Repligen Reports First Quarter Fiscal Year 2008 Financial Results
12:00am
from a Phase 2 clinical trial to evaluate the use of RG1068, synthetic human secretin, as an agent to improve the assessment of the pancreatic ducts … by magnetic resonance imaging (MRI). Detailed visual assessment of the pancreatic ducts and identification of structural abnormalities is important
8-K
EX-99.1
RGEN
Repligen Corp.
7 Aug 08
Repligen Reports First Quarter Fiscal Year 2009 Financial Results
12:00am
, to improve the assessment of pancreatic duct structures by magnetic resonance imaging (MRI). This study is designed to assess the sensitivity … and specificity of secretin-enhanced MRI to improve the ability to detect pancreatic duct abnormalities relative to MRI alone. Detailed visual assessment
8-K
EX-99
RGEN
Repligen Corp.
5 Jun 03
Financial statements and exhibits
12:00am
) sales, SecreFlo(TM)
sales, a product for pancreatic assessment that was launched in October 2002,
and research revenue. Gross profit for fiscal 2003 … for injection, is marketed to gastroenterologists for
pancreatic assessment and for use during a gastrointestinal procedure called
ERCP. Repligen's corporate
CORRESP
btbc3pm uupy1b
29 May 09
Correspondence with SEC
12:00am
8-K
EX-99.1
33zbr c68ar8
31 Jul 03
Current report
12:00am
8-K
EX-99.1
2nb8pe96lz03i4
9 Jun 10
Vice President, Market Development
12:00am
8-K
EX-99.1
pzng741vwmge7y37rct
9 Feb 11
Results of Operations and Financial Condition
12:00am
DEFR14A
d2jlszfm1fm5mxpsbh6
5 May 21
Revised proxy
4:16pm
8-K
EX-99.1
4p31b8hth
9 Apr 02
Other events
12:00am
8-K
EX-10.1
8zqnx3 cfj0
15 Jul 14
Departure of Directors or Certain Officers
12:00am